Abgenix
Abgenix is a biotechnology company dedicated to fighting deadly diseases such as cancer, diabetes, lung infections, and other infectious diseases. The company focuses on research, development of drugs, vaccines, and innovative therapies to improve health outcomes worldwide. Their mission is to create awareness, support research efforts, and develop less invasive treatments to combat global health challenges, including emerging threats like drug-resistant tuberculosis and cryptosporidiosis.
Industries
Nr. of Employees
medium (51-250)
Services
Regularly published blog posts and articles that summarize research findings, regulatory notices, and public health topics for a general audience and research students.
A contact form allowing readers to submit information or tips about research efforts and public-health topics to the site author.
Regularly published blog posts and articles that summarize research findings, regulatory notices, and public health topics for a general audience and research students.
A contact form allowing readers to submit information or tips about research efforts and public-health topics to the site author.
Expertise Areas
- Biomedical writing and science communication
- Research curation and evidence summarization
- Preclinical drug development and tumor model evaluation
- Tumor microenvironment and stromal biology
Key Technologies
- Rodent preclinical models
- 3D tumor spheroid culture
- Oncolytic virotherapy methods
- Vaccine bioprocessing and scale-up
News & Updates
The company was acquired in a landmark deal, selling for 2.2 billion dollars.
Funding has been allocated to research efforts targeting deadly lung diseases.
A vaccine facility has been established to produce vaccines rapidly in response to pandemics.
India is actively working to control the rise of drug-resistant tuberculosis.
Research has been conducted to develop methods for storing Cryptosporidium to aid future vaccine development.
A new drug called Metavert has shown promise in blocking the growth of pancreatic cancer in laboratory mice.
The company was acquired in a landmark deal, selling for 2.2 billion dollars.
Funding has been allocated to research efforts targeting deadly lung diseases.
A vaccine facility has been established to produce vaccines rapidly in response to pandemics.
India is actively working to control the rise of drug-resistant tuberculosis.
Research has been conducted to develop methods for storing Cryptosporidium to aid future vaccine development.
A new drug called Metavert has shown promise in blocking the growth of pancreatic cancer in laboratory mice.